Skip to content

Semantic Analysis by spaCy

Eisai Co. Ltd. & Anr. Vs.satish Reddy & Anr.

Decided On : May-06-2019

Court : Delhi

Notice (8): Undefined index: topics [APP/View/Case/meta.ctp, line 36]
Warning (2): Invalid argument supplied for foreach() [APP/View/Case/meta.ctp, line 39]

LAW: Page 1, Plaintiff No.2, Page 5, Section 8, the Patents Act, Page 10 of 37, Sections 83, the Patents Act, Section 48, the Patents Act, Page 11, Section 48, the Patents Act, the Exclusive Rights of a Patentee, section 83, Section 48, Sections 83, the Patents Act, the Patents Act, Section 3(d, Section 3(d, Section 3(d, Section 3(d, Page 13, Page 14, Plaintiff No.2, Page 15, Plaintiff No.2, Plaintiff No.2, Plaintiff No.2, Page 16, Section 3 (d, Section 3 (d, Section 3(d, the Patents Act, Section 64(1)(d, Section 2(1)(j, Section 64(1)(e, Section 64(1)(f, Section 64(1)(k, Section 3(e, Section 64(1)(k, Section 3(i, Page 21, the Patents Act, Page 24, Section 165 of Indian Evidence Act, Section 165, the Indian Evidence Act, Plaintiff No.2, Page 33, the Patents Act, Section 48, the Patents Act, Sections 83, the Patents Act, the Patents Act, Section 3(d, Section 2(1)(j, the Patents Act, Page 36, the Regular Bench

DATE: May, 2019, 13934/2018, 15885/2018, 13934/2018, 13934/2018, 37 2, the very first date i.e., 08th October, 2018, 08th October, 2018, January, 2019, 1996, 14th February, 2017, January, 2019, 1169/2018, the year 2001, next eight years, 2010, 2018, the last 15 years, almost 18 years, 2006, 2010 to 2018, 23rd September, 2004, 27th February, 2008, the period of, 20 years i.e., 11th April, 2003, 10th April, 2023, more than 10 years, March, 2019, 37 7, up to 10th April, late August, 2018, 28th August, 2018, October, Claims 38, 39, 1169/2018, Claims 38, 39, 29, 30, 2015, 14th January, 2019, 29th June, 2016, 2014, WO2003086306, more than 10 years, 22nd October, 2018, 2015, today, today, 2009, 16, 1930, recent years, 37, 2010, 1970, 1970, 2017, 1970, 79, a period of, two-three months, 37, 2005, 2005, end of March, 2019, March, 2019, November, 2018, December, 2018, 1940, 18 months, March, 2019, just 6 months, 2011-2017, 2010, 2014, 25th March, 2008, 19th May, 2008, 02nd May, 2018, 2296, 1208/KOLNP/2012, 1208, 09th April, 2012, 2296, 15th January, 2018, 27th April, 2017, 1208, 16th April, 2018, 2296, 2015, Del 8227, 2296, 2015, 2009 110, 2, 6, 7, 11, 12, 31, 36, 38, 39, 56, 1970, 2013, 1970, 1984, 2001, 2011, the last 5 years, financial year 2018, November, 2018, 29th October, 2018, 2296, November, 2018, 1208, 11th October, 2018, more than 15½ years, almost 11 years, 27th June, 2012, 2013, 2018, 2016, November, 2016, 2016, November, 2016, more than 15½ years, almost 10½ years, 2016, 27th June, 2012, June 2013, November, 2013, December, 2016, November, 2013, more than 2 years ago, November/December 2016, 2 years, 1998, 1998, 2011, 2009, Year, 2007, 2009, more than five years, 21st December, 2018, 14th January, 2019, 40 years, 37, July 2016, 42 years, the year 2015, about 1½ years, 2016, 1169/2018 Page 29, about 40 years, December, 2015, June 2016, 29th June, 2016, 29th June, 2016, the period 2013 to 2016, 08th November, 2016, 06th January, 2017, 06th January, 2017, 24th May, 2017, 24th May, 2017, 29th June, 2016, 29th June, 2016, 29th June, 1169/2018 Page 31, 37, 29th June, 2016, 03rd April, 2017, 1945, 03rd April, 2017, the year 2001, the next eight years, 2010, 2018, the last 15 years, almost 18 years, 2006, 2010 to 2018, 23rd September, 2004, 27th February, 2008, the period of, 20 years, 11th April, 2003, 10th April, 2023, more than 10 years, 14th January, 2019, 29th June, 2016, 37, 22nd December, 2018 &, January, 2019, 15th January, 2018, 16th April, 2018, 1970, 1970, 2017, 2005, 2005, 2015, 22nd October, 2018, 54, 1169/2018 57, 04th July, 2019, 2019

ORG: EISAI CO. LTD. & ANR, SATISH REDDY & ANR, No.215528, Lorcaserin Hydrochloride, Lorcaserin Hydrochloride Hemihydrate, Court, Reliance, Division Bench, Court, DRJ, DB).8, Reliance, Bayer Intellectual Property, GMBH, BDR Pharmaceuticals International Pvt, Japanese Pharmaceutical Company, CS, Lorcaserin, Lorcaserin, Lorcaserin, Lorcaserin, US Food and Drug Administration, USFDA, No.215528, LHH, Lorcaserin, the Subject Expert Committee, SEC, SEC, LHH, No.215528, Lorcaserin, LHH, Lorcaserin, Lorcaserin, 5HT2c Receptor, Lorcaserin, LHH, Reliance, MERCK, Sitagliptin Phosphate Monohydrate, Sitagliptin Phosphate Monohydrate, the Defendant for Indian Drug Regulations Affairs, PCT, PCT, Indian Patent Application, LHH, PCT, the Patent Office, Reliance, Merck, Glenmark, Court, Glenmark, MSD, SPM, Sitagliptin plus Metformin, Glenmark, SPM, MSD, Glenmark, CS, Glenmark, Reliance, Merck v. Glenmark, Court, Court, Bayer Corporation and Ors, Cipla, Union of India, Court, the Written Statement, LHH, LHH, CS, the Court of Appeals for England, Reddy’s Laboratories, Eli Lily, Eli Lily‟s, Olanzapine, Eli Lily, Court, Sherwood Forest, Sherwood Forest, Reliance, Merck, Roche, Cipla, the Patent Office, License, License, Cipla, CS, Court, LHH, CS, Reliance, Merck, Reliance, New Yash Engineers (Supra, the Indian Patent Office, IPO, the European Patent Office, no.2, IPO, LHH, Lorcaserin Hydrochloride, European Counterpart, LHH, EP1838677, the European Patent Office, Examiner, LHH, no.2, no.2, LH, Symed Labs Ltd., CS, the First Examination Report, FER, FER, no.2, the Directorate General of Health Services, LHH, CS, LHH, no.2, Reliance, Novartis AG v. Union of India 2013, Merck Sharp & Dohme Corporation, Glenmark Pharmaceuticals Ltd., DB).36, POSA, LHH, LHH, LHH, LHH, LHH, Markush, Lorcaserin, LH, LHH, LH, LHH, LHH, Lorcaserin, LH, LHH, POSA, the Patent Office, LH, LHH, the Indian Patent Office, LHH, LHH, POSA, LH, LHH, Lorcaserin, Court, LH, LHH, the Patent Office, LH, LHH, CS (COMM), Court, the Patent Office, Court, LHH, FER, the Patent Office, LH, LHH, Reliance, Merck Sharp & Dohme Corporation, Glenmark Pharmaceuticals Ltd., Roche, Cipla, Lorcaserin, LHH, 64(1)(o).39, Lorcaserin, Lorcaserin, Reliance, Novartis AG v. Union of India, Credible Challenge to Validity of the Suit Patent, the Suit Patent, Lupin Ltd. /, Lupin Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Lorcaserin, inter alia, CH194 and/or US639, US639, the Padhma Shri Award, the Padham Bhushan Award, BELVIQ, LHH, LHH, INR200,00,000 (Rupees, Bioequivalence, CS, CS, CS, Lorcaserin, Court, LHH, the last moment.48, LHH, Hypertension, IMS Rx, Orlistat, Orlistat, Fenfluramine, Dexfenfluramine, Sibutramine, CS, LHH, energy & money on development, LHH, dieticians, Court, Court, CS, Lorcaserin Hydrochloride Hemihydrate, the Patent Department, Emphasis, An Internal Committee, Committee, Committee, Astra Zeneca, Emphasis, Indian Drug Regulations Affairs, Lorcaserin Hydrochloride Hemihydrate, Business Strategic Unit, LHH, Directorate General of Health Services, LHH, LHH, the Research Development Unit, CS, LHH, LHH, Subject Experts Committee, III Clinical Trial, SEC, NOC, DGHS, Clinical Trial, LHH, NOC, Drugs Controller General, LHH, Mark-A, Emphasis, Lorcaserin, Lorcaserin, US Food and Drug Administration, USFDA, No.215528, LHH, No.215528, Lorcaserin, LHH, 2014/0187538A1, PCT, Indian Patent Application, LHH, PCT, CS, LHH, LHH, Court, Court, Court, License under Sections 83, Cipla, Court, CS, Merck, Glenmark, Court, the Plaintiffs‟ Indian Patent, CS, LHH

PERSON: Sudhir Chandra, Pravin Anand, Archana Sanker, Dhruv Anand, Vidisha Garg, Udita Patro, Nischay Mall, Saikrishna Rajagopal, Sneha Jain, Devvrat Joshi, Amitavo Mitra, Garima Sawhney, LHH‟, Franz Xaver Huemer, New Yash, Glenmark, CS, Formula, LH, Formula, Jacob, Generics, Emphasis Supplied, Emphasis Supplied, I. G. Farbenindustrie A.G.’s, John R, Reddy, Reddy, Novartis, Franz Xaver Huemer, New Yash Engineers, Franz Xaver, Girish Parhate, Franz Xaver Huemer, Glaverbel S.A. v., Dave Rose., Sandeep Jaidka, LH, LH, Symed Labs, LH, CS, CH194, Anji Reddy, LH, CS, Fatty, Good Health‟, Sadashiv Parhate, Poonam Raghuvanshi, Smitha Ramdas, Ramdas Manakkote, Aparna Sarovar, Poonam Raghuvanshi, Ticagrelor, Sadashiv Parhate, LHH‟, Q.1, Q.2, Girish Parhate, C-4, Girish Parhate, Emphasis Supplied, Novartis, Franz Xaver Huemer, New Yash Engineers, No.215528, J.CS

GPE: J.R., I.A., I.A., India, India, Lorcaserin, USA, South Korea, Taiwan, Israel, Brazil, India, India, US, LH, US, LH, India, India, piggy, Lorcaserin, LH, Lorcaserin, Sitagliptin, Sitagliptin, Lorcaserin, US, Lorcaserin, Lorcaserin, US, Smithkline, Wales, UK, India, India, India, India, India, Lorcaserin, Lorcaserin, LH, Lorcaserin, LH, Lorcaserin, Lorcaserin, Lorcaserin, LH, LH, Lorcaserin, Lorcaserin, Lorcaserin, Lorcaserin, LH, Lorcaserin, LH, chloro, US, US, GB324, GB324, India, India, US, Canada, India, XP-23829, Lorcaserin, LH, India, India, USA, India, DCGI, India, India, India, India, India, India, India, India, US, US, India, India, India, India, India, India, DCGI, DCGI, India, Ameenpur, Ameenpur, India, Lorcaserin, Lorcaserin, USA, South Korea, Taiwan, Israel, Brazil, Mexico, India, India, US, Lorcaserin, Lorcaserin, US, India, India, India

WORK_OF_ART: Lorcaserin, Lorcaserin, CS (COMM), Drugs and Cosmetics Act, CS (COMM), Lorcaserin Hydrochloride Hemihydrate, Lorcaserin, Lorcaserin

CARDINAL: 5, 37, 3, 4, 2, 37, over 8,000, over 12,000, over 20,000, over 65, six, 3, 38, 2023.8, 112, 2018.9, more than 18, 4, 54, 5HT2c, 63, 100, 38, 39, 223, 75, 37, 2014/0187538A1, 8, 20-23, 6, 37, 63, 7, 37, 15, 162, 8, 37, three, 47, 321, two, 9, 18, two, two, millions, 21, 65, 84, 70, 37, 12, 84, two, 37, 105, 25, more than 15, 37, 43, 2970.26, No.2, No.2, No.2, 37, 37, 6, 1, thousands, millions, one, 38, at least 1620, 17, 37, 31, 311, 18, 37, 1, 59 to 67, 38, 39, 64(1)(e, 5HT2C, 5HT2C, 19, 37, 6, two, 20, more than 350, more than 300, about 26, more than 180, more than 80, more than 40, more than 100, 9, nine, more than 1200, one thousand two hundred, 311, 12,000, 22, 37, 300, 2500, Two, One, 23, 37, 37, around 153 million, about 135 million, five, 25, 37, 65, more than 65, only six, six, four, two, 26, 37, about 15.3, 13.5, 2, 27, 37, 1872.49, 3A, 164, 502032, 28, 37, five, five, 3A, 164, 3, 30, 37, C2, 8, 8, 8, 50, over 8,000, over 12,000, over 20,000, 50.2, over 65, six, 32, 37, 50.4, 38, 39, 50.6, 50.8, 50.9, 50.10, 11, 34, 37 50.11, 84, 50.12, 84, 50.13, 64(1)(e, 35, 64(1, 3(e, 3(i, 63, 52, 37, 37, 37

NORP: Indian, Indian, Indian, Indian, Indian, Indian, Indian, Indian, Indian, Indian, Indian, Indian, Indian, Indian, obese, Plaintiffs‟, Indian, obese, obese, Indian, Nallagandla

MONEY: approximately 1 billion dollars, millions of dollars, 311/KOLNP/2009, 223 DLT454and, one billion dollars

ORDINAL: third, 5th, first, first, first, second, third, first, third, first, second, first, First, second, second, third, third, 06th, 31st, third, first

PRODUCT: GB324, CH194, XenoPort, No.1, No.1, Plaintiff No.2

LOC: Europe, Plaintiff no.2

PERCENT: 13%, more than 90%, 5%-10%, less than 10%

FAC: Phase-III Clinical, Lorcaserin Hydrochloride

EVENT: Lorcaserin

View Full Judgment


Save Judgments// Add Notes // Store Search Result sets // Organize Client Files //